Skip to content
sellWeak cluster of 310b5-1 plan

Richard S Levy sold $4.4M of MDGL

director at MADRIGAL PHARMACEUTICALS, INC.. 8,500 shares at an average of $520.96, traded Nov 13, 2025, filed Nov 14, 2025.

Warning score
30
Value
$4.4M
8,500 shares
Holdings after
21,197
-29% from before
From 52-week low
+92%
low $267.56, close $514.93
From 52-week high
-5%
high $541.50, as of Nov 13, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $4.4M at market
    +25
  • Share of holdings sold
    Sold 29% of holdings
    +10
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

MDGLOct 9, 2026 · close 471.75
Since filing Nov 14, 2025: -10.9%SPY +17.1% · excess -28.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001628280-25-052411, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 13, 2025MOption exercise
Common Stock10b5-1
+2,500$7.36$18k23,697Nov 14, 2025
Nov 13, 2025MOption exercise
Common Stock10b5-1
+6,000$16.46$99k29,697Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-146$514.67$75k29,551Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-919$515.64$474k28,632Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-645$517.51$334k27,987Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-835$518.53$433k27,152Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-1,355$519.67$704k25,797Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-308$520.68$160k25,489Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-1,094$521.79$571k24,395Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-1,434$522.70$750k22,961Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-811$523.66$425k22,150Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-153$524.49$80k21,997Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-120$526.68$63k21,877Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-200$527.85$106k21,677Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-440$528.60$233k21,237Nov 14, 2025
Nov 13, 2025SOpen-market sale
Common Stock10b5-1
-40$530.21$21k21,197Nov 14, 2025
Nov 13, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-2,500$0.00$02,500Nov 14, 2025
Nov 13, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-6,000$0.00$04,000Nov 14, 2025

Related signals

Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
MDGLsell10b5-1
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$6.2M
11,583 shares
-6%
25Weak
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Paul A Friedman
director
$14M
24,800 shares
-12%
20Weak
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Rebecca Taub
director
$10M
18,650 shares
-4%
50Moderate
MDGLsell 5
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$1.4M
2,400 shares
-2%
37Weak
MDGLsell 510b5-1
MADRIGAL PHARMACEUTICALS, INC.
Mardi Dier
EVP and CFO
$2.4M
4,173 shares
-29%
40Moderate
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Carole Huntsman
Chief Commercial Officer
$1.1M
1,958 shares
-16%
53Moderate
MDGLsell 2
MADRIGAL PHARMACEUTICALS, INC.
Kenneth Bate
director
$8.0M
16,575 shares
-86%
50Moderate
MDGLsell
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$3.2M
7,279 shares
-7%
45Moderate
MDGLsell 510b5-1
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$3.0M
7,616 shares
-6%
46Moderate
MDGLbuy
MADRIGAL PHARMACEUTICALS, INC.
Baker Bros. Advisors LP
director
$25M
68,618 shares
+36%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Richard S Levy sold $4.4M of MDGL | InsiderTell